**Amendments to the Claims:**

The following listing of claims will replace all prior versions of the claims in the application referenced above.

**Listing of Claims:**

Claims 1-45 (canceled)

Claim 46 (new): A pharmaceutical composition comprising a daily dose of a valproate compound wherein the composition, when provided once a day to a steady state population of patients, provides an essentially flat average pharmacokinetic curve such that the plasma concentration levels vary within a range of about 30 μg/ml.

Claim 47 (new): The composition of claim 46 wherein in the valproate compound is divalproex sodium.

Claim 48 (new): The composition of claim 46 wherein the flat average pharmacokinetic maintains a plasma level of valproate within a therapeutic range.

Claim 49 (new): The composition of claim 48 wherein the composition is provided as one or more dosage units collectively containing the daily dose of the valproate compound.

Claim 50 (new): The composition of claim 49 wherein the valproate compound is divalproex sodium.

Claim 51 (new): The composition of claim 47wherein the composition further provides a mean steady-state $AUC_{0-24}$ measurement of valproate that is at least 80% of the mean steady-state $AUC_{0-24}$ measurement of valproate provided by an enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 52 (new): The composition of claim 51 wherein the composition further provides a mean steady-state Cmax of valproate that is statistically significantly lower than the mean steady-state Cmax of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 53 (new): The composition of claim 52 wherein the mean steady-state degree of fluctuation of valproate provided by the composition is less than the mean steady-state degree of fluctuation of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 54 (new):The composition of claim 53 wherein the mean steady-state Tmax of valproate provided by the composition is at least twice as long as the mean steady-state Tmax of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 55 (new): The composition of claim 54 wherein the mean steady-state Cmin of valproate provided by the composition is not statistically different than the mean steady-state Cmin of valproate provided by the enteric-coated delayed-release divalproex sodium tablet given twice a day.

Claim 56 (new): A pharmaceutical composition comprising a daily dose of a valproate compound wherein the composition, when provided once a day to a steady state population of patients, provides a mean Cmin of about 48 or higher.

Claim 57 (new): The pharmaceutical composition of claim 56 wherein the valproate compound is divalproex sodium.

Claim 58 (new): The pharmaceutical composition of claim 57 wherein the composition further provides an essentially flat average pharmacokinetic curve such that the plasma concentration levels vary within a range of about 30 μg/ml.

Claim 59 (new): The composition of claim 58 wherein the composition is provided as one or more dosage units collectively containing the daily dose of divalproex sodium.